IL-4 Monoclonal antibody

<strong>IL-4 Monoclonal antibody</strong>_x000D_ <strong>Catalog number:</strong> B2015345_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20¬∞C_x000D_ <strong>Keywords:</strong> IL-4 Monoclonal antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Le Floc'h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Bai Y, Lim WK, Martin J, Huang T, Potocky TB, Kim JH, Rafique A, Papadopoulos NJ, Stahl N, Yancopoulos GD, Murphy AJ, Sleeman MA, Orengo JM. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4RŒ± antibody, is required to broadly inhibit type 2 inflammation Allergy. 2020 May;75(5):1188-1204._x000D_ 2: Seegr√§ber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis Expert Rev Clin Pharmacol. 2018 May;11(5):467-474._x000D_ 3: Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis N Engl J Med. 2016 Dec 15;375(24):2335-2348._x000D_ 4: Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov. 2016 Jan;15(1):35-50._x000D_ 5: Walsh GM. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update Expert Rev Clin Immunol. 2017 Feb;13(2):143-149._x000D_ 6: Bury J, Zirwas M. Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade J Drugs Dermatol. 2023 Oct 1;22(10):1007-1008._x000D_ 7: Matsunaga MC, Yamauchi PS. IL-4 and IL-13 Inhibition in Atopic Dermatitis J Drugs Dermatol. 2016 Aug 1;15(8):925-9._x000D_ 8: Chiarella SE, Sy H, Peters AT. Monoclonal antibody therapy in sinonasal disease Am J Rhinol Allergy. 2017 Mar 1;31(2):93-95._x000D_ 9: Tang CL, Pan Q, Dai WQ, Hu LD, Zhou HH, Wang LX. Administration of anti-CTLA-4 monoclonal antibody augments protective immunity induced by Schistosoma japonicum glutathione-S-transferase Parasite Immunol. 2019 Aug;41(8):e12657._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/1602140">10: Haak-Frendscho M, Brown JF, Iizawa Y, Wagner RD, Czuprynski CJ. Administration of anti-IL-4 monoclonal antibody 11B11 increases the resistance of mice to Listeria monocytogenes infection J Immunol. 1992 Jun 15;148(12):3978-85.</a>_x000D_ _x000D_ <strong>Products Related to IL-4 Monoclonal antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>